MDR gene expression analysis of six drug-resistant ovarian cancer cell lines

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Januchowski, Radosław ^a   Wojtowicz, Karolina ^a   Sujka Kordowska, Patrycja ^a   Andrzejewska, Małgorzata ^a   Zabel, Maciej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TOPOTECAN; VINCRISTINE; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; DRUG EFFECTS;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS;

EID: 84874630030     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/241763     Document Type: Article

References (47)

1. Kurman R. J., Blaustein's Pathology of the Female Genital Tract 2002 5th New York, NY, USA Springer
2. The ICON and AGO Collaborators, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361 2099 2106
3. Pfisterer J., Plante M., Vergote I., Du Bois A., Hirte H., Lacave A. J., Wagner U., Stähle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Lück H. J., Rochon J., Zimmermann A. H., Eisenhauer E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of Clinical Oncology 2006 24 29 4699 4707 2-s2.0-33750588670 10.1200/JCO.2006.06.0913 (Pubitemid 46630933)
4. Pujade-Lauraine E., Mahner S., Kaern J., Gebski M., Heywood P., Vasey A., A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). Journal of Clinical Oncology 2009 27 18, abstract LBA5509
5. Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A. G., Sommer H., Klare P., Stauch M., Paulenz A., Camara O., Keil E., Lichtenegger W., Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of Clinical Oncology 2008 26 19 3176 3182 2-s2.0-49249130845 10.1200/JCO.2007.15.1258
6. Mutch D. G., Orlando M., Goss T., Teneriello M. G., Gordon A. N., McMeekin S. D., Wang Y., Scribner D. R., Marciniack M., Naumann R. W., Secord A. A., Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology 2007 25 19 2811 2818 2-s2.0-34447570846 10.1200/JCO.2006.09. 6735 (Pubitemid 47123191)
7. Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., Del Medico P., Scaltriti L., Katsaros D., Priolo D., Scambia G., Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of Clinical Oncology 2008 26 6 890 896 2-s2.0-39749113438 10.1200/JCO.2007.13.6606 (Pubitemid 351398081)
8. Stavrovskaya A. A., Cellular mechanism of multidrug resistance of tumor cells. Biochemistry 2000 65 1 95 106 2-s2.0-0033628853
9. Gottesman M. M., Mechanisms of cancer drug resistance. Annual Review of Medicine 2002 53 615 627 2-s2.0-0036176510 10.1146/annurev.med.53.082901.103929 (Pubitemid 34177898)
10. Kruh G. D., Introduction to resistance to anticancer agents. Oncogene 2003 22 47 7262 7264 2-s2.0-0345688619 10.1038/sj.onc.1206932 (Pubitemid 37487158)
11. Ozben T., Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Letters 2006 580 12 2903 2909 2-s2.0-33646568511 10.1016/j.febslet.2006.02.020 (Pubitemid 43729172)
12. Leonard G. D., Fojo T., Bates S. E., The role of ABC transporters in clinical practice. Oncologist 2003 8 5 411 424 2-s2.0-0141888537 10.1634/theoncologist.8-5-411 (Pubitemid 37238869)
13. Choi C. H., ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell International 2005 5, article 30 2-s2.0-27644577664 10.1186/1475-2867-5-30 (Pubitemid 41554983)
14. Abolhoda A., Wilson A. E., Ross H., Danenberg P. V., Burt M., Scotto K. W., Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clinical Cancer Research 1999 5 11 3352 3356 2-s2.0-0032713821
15. Al-Katib A. M., Smith M. R., Kamanda W. S., Pettit G. R., Hamdan M., Mohamed A. N., Chelladurai B., Mohammad R. M., Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clinical Cancer Research 1998 4 5 1305 1314 2-s2.0-0031924260 (Pubitemid 28213344)
16. Podolski-Renić A., Andelković T., Banković J., Tanić N., Ruždijić S., Pešić M., The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomedicine and Pharmacotherapy 2011 65 5 345 353 2-s2.0-79960967691 10.1016/j.biopha.2011.04.015
17. Cole S. P. C., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M. V., Deeley R. G., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992 258 5088 1650 1654 2-s2.0-0027095653 (Pubitemid 23012438)
18. Fardel O., Jigorel E., Le Vee M., Payen L., Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomedicine and Pharmacotherapy 2005 59 3 104 114 2-s2.0-15744368796 10.1016/j.biopha.2005.01.005 (Pubitemid 40417519)
19. Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dolinska-Krajewska B., Gebarowska E., Dietel M., Zabel M., Lage H., ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clinical Cancer Research 2006 12 23 7149 7158 2-s2.0-33845724571 10.1158/1078-0432.CCR-06-0564 (Pubitemid 44974516)
20. Guminski A. D., Balleine R. L., Chiew Y. E., Webster L. R., Tapner M., Farrell G. C., Harnett P. R., DeFazio A., MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology 2006 100 2 239 246 2-s2.0-30444454344 10.1016/j.ygyno.2005.08.046 (Pubitemid 43075256)
21. Austin Doyle L., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D., A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998 95 26 15665 15670 2-s2.0-13044249156 10.1073/pnas.95.26. 15665 (Pubitemid 29018757)
22. Robey R. W., Polgar O., Deeken J., To K. W., Bates S. E., ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews 2007 26 1 39 57 2-s2.0-33947381412 10.1007/s10555-007-9042-6 (Pubitemid 46452182)
23. Maliepaard M., Van Gastelen M. A., De Jong L. A., Pluim D., Van Waardenburg R. C. A. M., Ruevekamp-Helmers M. C., Floot B. G. J., Schellens J. H. M., Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Research 1999 59 18 4559 4563 2-s2.0-0033568540 (Pubitemid 29428958)
24. Scheffer G. L., Schroeijers A. B., Izquierdo M. A., Wiemer E. A. C., Scheper R. J., Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Current Opinion in Oncology 2000 12 6 550 556 2-s2.0-0034501399 10.1097/00001622-200011000-00007 (Pubitemid 32039654)
25. Laurencot C. M., Scheffer G. L., Scheper R. J., Shoemaker R. H., Increased LRP Mrna expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. International Journal of Cancer 1997 72 1021 1026 (Pubitemid 27433568)
26. Berger W., Elbling L., Micksche M., Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-team exposure to antineoplastic drugs. International Journal of Cancer 2000 88 293 300
27. Behrens B. C., Hamilton T. C., Masuda H., Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Research 1987 47 2 414 418 2-s2.0-0023111825 (Pubitemid 17009602)
28. Dolfini E., Dasdia T., Arancia G., Molinari A., Calcabrini A., Scheper R. J., Flens M. J., Gariboldi M. B., Monti E., Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. British Journal of Cancer 1997 76 1 67 76 2-s2.0-0030950351 (Pubitemid 27250078)
29. Dietel M., Bals U., Schaefer B., Herzig I., Arps H., Zabel M., In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumours. European Journal of Cancer Part A 1993 29 3 416 420 2-s2.0-0027470899 (Pubitemid 23025753)
30. Hennessy B. T., Coleman R. L., Markman M., Ovarian cancer. Lancet 2009 374 371 382
31. Raggers R. J., Vogels I., Van Meer G., Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochemical Journal 2001 357 3 859 865 2-s2.0-0035425507 10.1042/0264-6021:3570859 (Pubitemid 32735167)
32. Ho M. M., Ng A. V., Lam S., Hung J. Y., Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research 2007 67 10 4827 4833 2-s2.0-34250306257 10.1158/0008-5472.CAN-06-3557 (Pubitemid 46910191)
33. Raaijmakers M. H. G. P., De Grouw E. P. L. M., Van Der Reijden B. A., De Witte T. J. M., Jansen J. H., Raymakers R. A. P., ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clinical Cancer Research 2006 12 11 I 3452 3458 2-s2.0-33745190916 10.1158/1078-0432.CCR-05-1945
34. Gottesman M. M., Fojo T., Bates S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002 2 1 48 58 2-s2.0-0036364467 (Pubitemid 37328807)
35. Vlaming M. L. H., Pala Z., Van Esch A., Wagenaar E., De Waart D. R., Van De Wetering K., Van Der Kruijssen C. M. M., Oude Elferink R. P. J., Van Tellingen O., Schinkel A. H., Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clinical Cancer Research 2009 15 9 3084 3093 2-s2.0-65649094824 10.1158/1078-0432.CCR-08-2940
36. Vlaming M. L. H., Pala Z., Van Esch A., Wagenaar E., Van Tellingen O., De Waart D. R., Oude Elferink R. P. J., Van De Wetering K., Schinkel A. H., Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clinical Cancer Research 2008 14 24 8152 8160 2-s2.0-58149359768 10.1158/1078-0432.CCR-08-1609
37. Liedert B., Materna V., Schadendorf D., Thomale J., Lage H., Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Journal of Investigative Dermatology 2003 121 1 172 176 2-s2.0-0041342087 10.1046/j.1523-1747.2003.12313.x (Pubitemid 36900469)
38. Ishikawa T., Ali-Osman F., Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. Journal of Biological Chemistry 1993 268 27 20116 20125 2-s2.0-0027305406 (Pubitemid 23278910)
39. Kase H., Kodama S., Nagai E., Tanaka K., Glutathione S-transferase π immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytologica 1998 42 6 1397 1402 2-s2.0-0032436607 (Pubitemid 29005951)
40. Kasahara K., Fujiwara Y., Nishio K., Ohmori T., Sugimoto Y., Komiya K., Matsuda T., Saijo N., Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Research 1991 51 12 3237 3242 2-s2.0-0025781307
41. Yang C. H., Schneider E., Kuo M. L., Volk E. L., Rocchi E., Chen Y. C., BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochemical Pharmacology 2000 60 6 831 837 2-s2.0-0034666736 10.1016/S0006-2952(00)00396-8 (Pubitemid 30621668)
42. Ishii M., Iwahana M., Mitsui I., Minami M., Imagawa S., Tohgo A., Ejima A., Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anti-Cancer Drugs 2000 11 5 353 362 2-s2.0-0033911659 10.1097/00001813- 200006000-00005 (Pubitemid 30459470)
43. Vanhoefer U., Müller M. R., Hilger R. A., Lindtner B., Klaassen U., Schleucher N., Rustum Y. M., Seeber S., Harstrick A., Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. British Journal of Cancer 1999 81 8 1304 1310 2-s2.0-0032739648
44. Leggas M., Adachi M., Scheffer G. L., Sun D., Wielinga P., Du G., Mercer K. E., Zhuang Y., Panetta J. C., Johnston B., Scheper R. J., Stewart C. F., Schuetz J. D., Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Molecular and Cellular Biology 2004 24 17 7612 7621 2-s2.0-4344632950 10.1128/MCB.24.17.7612-7621.2004 (Pubitemid 39121487)
45. Norris M. D., de Graaf D., Haber M., Kavallaris M., Madafiglio J., Gilbert J., Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. International Journal of Cancer 1996 65 613 619 (Pubitemid 26092290)
46. Gifford A. J., Kavallaris M., Madafiglio J., Matherly L. H., Stewart B. W., Haber M., P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. International Journal of Cancer 1998 78 176 181 (Pubitemid 28443174)
47. De Graaf D., Sharma R. C., Mechetner E. B., Schimke R. T., Roninson I. B., P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proceedings of the National Academy of Sciences of the United States of America 1996 93 3 1238 1242 2-s2.0-0030052748 10.1073/pnas.93.3.1238 (Pubitemid 26052872)